Georgia Litsas

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence
    Georgia Litsas
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Oncol Nurs Forum 35:714-21. 2008
  2. doi Individualizing care for women with early-stage breast cancer: the role of molecular assays
    Georgia Litsas
    Breast Oncology Center, Dana Farber Cancer Institute, Boston, MA, USA
    Clin J Oncol Nurs 17:332-4. 2013
  3. doi Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer
    Georgia Litsas
    Breast Oncology Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin J Oncol Nurs 15:674-81. 2011
  4. pmc Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
  5. ncbi Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy
    Davinia S E Seah
    From the aDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, and bDepartment of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio
    J Natl Compr Canc Netw 12:71-80. 2014
  6. ncbi Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 7:158-61. 2006

Collaborators

Detail Information

Publications6

  1. doi Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence
    Georgia Litsas
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Oncol Nurs Forum 35:714-21. 2008
    ..To review the available evidence for the emerging role of aromatase inhibitors (AIs) in postmenopausal women with hormone-sensitive early-stage breast cancer...
  2. doi Individualizing care for women with early-stage breast cancer: the role of molecular assays
    Georgia Litsas
    Breast Oncology Center, Dana Farber Cancer Institute, Boston, MA, USA
    Clin J Oncol Nurs 17:332-4. 2013
    ..However, oncologists now are able to use molecular assays as a component of decision making for adjuvant therapy. This article focuses on the use of two of those molecular assays and their implications for nurses...
  3. doi Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer
    Georgia Litsas
    Breast Oncology Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin J Oncol Nurs 15:674-81. 2011
    ..This article provides oncology nurses with the knowledge needed to educate patients on the use of fulvestrant, to effectively administer this medication, and to prevent and manage potential side effects...
  4. pmc Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
    ..In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration...
  5. ncbi Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy
    Davinia S E Seah
    From the aDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, and bDepartment of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio
    J Natl Compr Canc Netw 12:71-80. 2014
    ..The role of advanced (greater than third) chemotherapy lines in improving survival of all patients with MBC warrants further study. ..
  6. ncbi Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 7:158-61. 2006
    ..We believe clinicians should be aware of the potential ovarian reserve among women with treatment-related amenorrhea so as to avoid use of AI therapy in patients in whom there is uncertainty about menopausal status...